Table 8 Characteristics of the largest community at the first level for the drug pipeline layer and the three largest sub-communities at the second level
From: Multilayer network analysis of the drugs development cycle in the global pharmaceutical industry
\(G_1\): Drug pipeline | ||||
|---|---|---|---|---|
Index | Size | Country | Category | Bow tie |
(a) the largest community | ||||
1: | 3380 | US (48.5) | Private company (76.7) | TE (31.5) |
JPN (7.6) | Public company (12.6) | IN (27.3) | ||
GBR (7.2) | Educational institution (9.9) | OUT (27.1) | ||
GSCC (14.1) | ||||
(b) 3 largest sub-communities | ||||
1:1: | 68 | US (66.7) | Private company (73.5) | OUT (36.8) |
ISR (7.4) | Educational institution (11.8) | IN (32.4) | ||
Public Company (10.3) | GSCC (17.6) | |||
TE (13.2) | ||||
1:3: | 66 | US (59.4) | Private company (83.3) | OUT (37.9) |
CAN (6.2) | Public company (10.6) | GSCC (25.8) | ||
JPN (6.2) | TE (18.2) | |||
GBR (6.2) | IN (18.2) | |||
1:7: | 63 | US (50.0) | Private company (81.0) | OUT (42.9) |
CAN (7.7) | Public company (12.7) | IN (28.6) | ||
GBR (7.7) | Educational institution (6.3) | TE (15.9) | ||
GSCC (12.7) | ||||